select count(*) as counts from cancer where `biomolecule` LIKE '%miRNA%'

Browse Biomarkers Based on Biomolecules

This page shows data for miRNA biomolecule.
Total Entries Retrieved: 263
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
523 hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227; miRNA Humans Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1]; Prognostic Localised Vs Metastatic Prostate Cancer p<0.0098 Serum 20473869
524 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Differentially Expressed Prognostic Pathoglical Stage pt3 vs pt2 p<0.05 Serum 20473869
525 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Upregulated Prognostic Gleason Score 6 Vs Gleason Score 7 p<0.05 Serum 20473869
526 miRNA-375 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.01 Serum 20473869
527 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.05 Serum 20473869
528 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Gleason Score >8 Vs Gleason Score 7 p<0.01 Serum 20473869
529 miRNA-375 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
530 miRNA-141 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
570 miR-874, -1274a, -1207-5p, -93, and -106a miRNA Humans Upregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001 Serum 21098088
571 miR- 223, -26b, -30c, and -24 miRNA Humans Downregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005; Serum 21098088
572 miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874 miRNA Humans Upregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003 Serum 21098088
573 miR-223; miR-24; miRNA Humans Downregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-223 p= 0.002; miR-24 p=0.02 Serum 21098088
607 let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93 miRNA Humans Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
608 miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star miRNA Humans Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
609 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001); Tissue 21400514
610 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
611 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001); Tissue 21400514
612 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
613 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001); Tissue 21400514
614 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
667 NA miRNA Humans Downregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
668 NA miRNA Humans Upregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
669 miR-143 miRNA Humans Downregulated in Bone Metastatis: 12.9 fold Prognostic Primary vs Bone Metastatis p=0.012 Tissue 21647377
670 miR-145 miRNA Humans Downregulated in Bone Metastatis: 17.3 fold Prognostic Primary vs Bone Metastatis p=0.014 Tissue 21647377
671 miR-143 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.039 Tissue 21647377
672 miR-145 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.041 Tissue 21647377
679 miR-141 miRNA Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p<0.001 Plasma 21723797
685 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
686 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
687 miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 miRNA Humans NA Prognostic group I (good prognosis) from group II (poor prognosis) p=0.0005 Tissue 21765474
770 miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p miRNA Humans Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
771 miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p miRNA Humans Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
795 mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887 miRNA Mice Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215] Diagnostic TRAMP and wild-type (WT) littermate control mice p≤ 0.05 Serum 22052531
796 hsa-mir-141; hsa-mir-298; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375] Diagnostic Normal Vs Primary Tumor p≤ 0.05 Serum 22052531
797 hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375] Diagnostic Normal Vs Metastatic Tumor p≤ 0.05 Serum 22052531
798 hsa-mir-375 miRNA Humans High expression associated with an increased risk of BCR Prognostic Biochemical Recurrenece p = 0.002 Serum 22052531
799 hsa-mir-375 miRNA Humans High expression with reduced chances of relapse free survival Prognostic Biochemical Recurrenece Univariate: p=0.0001; Multivariate: p=0.0260 Serum 22052531
815 miRNA - 221 and miRNA-222 miRNA Humans Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
837 mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs prostate cancer p<0.001 Plasma 22240788
838 mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs localised prostate cancer p<0.001 Plasma 22240788
839 mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b miRNA Humans Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)] Diagnostic metastatic prostate cancer Vs localised prostate cancer p<0.001 Plasma 22240788
840 miRNA - 107 miRNA Humans Upregulated in Pca Diagnostic Benign Vs Prostate Cancer p=0.001 Urine 22240788
841 miRNA - 574-3p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Prostate Cancer p=0.012 Urine 22240788
843 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p<0.001 Plasma 22298030
844 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Plasma 22298030
845 let-7c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
846 let-7e miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
847 miR-30c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
848 miR-622 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
849 miR-1285 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p=0.0047 Plasma 22298030
850 let-7c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training & Testing: p<0.0001 Plasma 22298030
851 let-7e miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p=0.0029; Testing = p<0.0001 Plasma 22298030
852 miR-25 miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
853 miR-30c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
854 miR-346 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
855 miR-622 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
856 miR-940 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p= 0.0062 Plasma 22298030
857 miR-1285 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
885 miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
886 miR143; miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
969 hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 miRNA Humans Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] Prognostic LowRisk(LR) Vs Metastatic CRPC p<0.0001 Serum 22887127
970 miR-375; miR-141; miR-378*; miRNA Humans Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] Prognostic Normal Vs Primary Tumor p<0.0001 Tissue 22887127
971 miR-375; miR-141; miR-378*; miR-409-3p miRNA Humans Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] Prognostic Normal Vs Low Risk Prostate Cancer miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] Tissue 22887127
1029 miR-30d miRNA Humans Upregulated in PCa Cell Lines (> 2 fold) Diagnostic Normal Vs Cancerous Prostate Cell Lines p<0.05 Cell Lines 23231923
1030 miR-30d miRNA Humans Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)] Diagnostic Cancerous Vs Cancer Adjacent from Same patient p = 0.03 Tissue 23231923
1031 miR-30d miRNA Humans Shorter Survival Time in High miRNA-30d group Prognostic Biochemical Recurrence p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) Tissue 23231923
1064 miR-141 miRNA Humans Upregulated in Bone Metastasis Prognostic Patients with Bone Metastasis Vs No Bone Metastasis p<0.001 Serum 23377530
1085 miR-183 miRNA Humans Upregulated in PC Cells Diagnostic Prostate Cancer Cell Lines Vs Normal Prostate Cell Lines p<0.05 Cell Lines 23538390
1086 miR-183 miRNA Humans Upregulated in Prostate Cancer Diagnostic prostate tumour Vs adjacent normal tissues p<0.05 Tissue 23538390
1087 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Tumor Stage pT2 Vs pT3 p<0.05 Tissue 23538390
1088 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Overall Survival p<0.05 Tissue 23538390
1091 miR-141 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1092 miR-375 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1093 miR-151-3p miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1094 miR-126 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1095 miR-16 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1096 miR-205 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1097 PSA + miR141 + mir-151-3p + mir-16 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1098 miR-423-3p miRNA Humans Upregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.002 Plasma 23574937
1099 miR-205 miRNA Humans Downregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.004 Plasma 23574937
1100 miR-205 miRNA Humans Upregulated in Biochemical Recurrence Prognostic Biochemical recurrence p = 0.006 Plasma 23574937
1101 miR-423-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1102 miR-151-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1123 miR-24 miRNA Mice Upregulated in TRAMP Mice Diagnostic TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice p < 0.01 Serum 23719956
1140 hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372 miRNA Humans Upregulated with fold change > 2 Diagnostic prostate tumor Vs normal epithelium p<0.05 Tissue 23781281
1141 let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 miRNA Humans Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] Prognostic Clinical progression free survival (CPFS) Vs. clinical failure (CF) p<0.05 Tissue 23798998
1142 let-7a; let-7b; let-7c miRNA Humans Downregulated in PCa: [let-7a; let-7b; let-7c] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Tissue 23798998
1170 miR-141 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.007 Serum 23846169
1171 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.008 Serum 23846169
1172 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.044 Serum 23846169
1173 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.02 Serum 23846169
1174 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.029 Serum 23846169
1199 miR-210 miRNA Humans Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) p=0.022 Serum 23935962
1200 miR-141 miRNA Humans Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p<0.0001; Testing: p<0.001 Serum 23935962
1201 miR-200a miRNA Humans Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.007; Testing: p=NS Serum 23935962
1202 miR-200c miRNA Humans Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.017; Testing: p=NS Serum 23935962
1203 miR-375 miRNA Humans Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.009; Testing: p=0.021 Serum 23935962
1204 hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c; miRNA Humans Upregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1205 hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96; miRNA Humans Downregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1224 hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a; miRNA Humans miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p ≤ 0.046 Tissue 24167554
1225 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1226 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1227 miR-221 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 24167554
1228 miR-99b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1229 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1230 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1231 miR-205+ miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1321 miR-25; miR-101;miR-628-5p miRNA Humans Differentially Expressed Diagnostic African Americans Vs Caucasian Americans with PCa p<0.05 Serum 24477576
1322 miR-25 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0109 Serum 24477576
1323 miR-101 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0006 Serum 24477576
1324 miR-628-5p miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p<0.0001 Serum 24477576
1333 U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p; miRNA Humans Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1334 miR-182 miRNA Humans Upregulated in PCa (4.7 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.717 Tissue 24518785
1335 miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.052 Tissue 24518785
1336 PSA+PCA3+miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1339 miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-483-5p; miR-486-3p; miR-563; miR-940; miRNA Humans Downregulated in PCa: miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-486-3p; miR-563; miR-940; Upregulated in PCa: miR-483-5p Diagnostic Prostate Cancer Vs Healthy Controls p<0.01 Urine 24563673
1340 miR-1825 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1341 miR-484 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1342 miR-1825 + miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1343 miR-1825 + miR-484 + PSA miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1351 miR-221 miRNA Humans Downregulation in high-risk prostate cancer Prognostic Cancer Related Death Vs No Cancer Related Death p<0.0001 Tissue 24607843
1370 hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b; miRNA Humans NA Prognostic High Vs Intermediate Vs Low risk p<0.05 Blood 24661838
1382 miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429 miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429] Prognostic PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1383 miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p; miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;] Prognostic DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1384 mir-200c miRNA Humans Upregulated in Non Responders (Median NR/median R): 1.6 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1385 mir-200b miRNA Humans Upregulated in Non Responders (Median NR/median R): 2.7 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1386 mir-146a miRNA Humans Downregulated in Non Responders (Median NR/median R): 1.4 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.05 Blood 24714754
1387 mir-222 miRNA Humans Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.01 Blood 24714754
1388 mir-301b miRNA Humans Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1389 mir-20a miRNA Humans Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1390 mir-200c + mir-200b + mir-146a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.001 Blood 24714754
1391 mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder -Post Docetaxel Change p = 0.02 Blood 24714754
1392 mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes) p=0.001 Blood 24714754
1396 miR-224 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000628 Tissue 24737792
1397 miR-452 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000494 Tissue 24737792
1398 Methylation status of GABRE + miR-224 +miR-452 miRNA + Methylation Humans Hypermethylated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.001 Tissue 24737792
1399 Methylation status of GABRE + miR-224 +miR-452 (as continous value ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1400 Methylation status of GABRE + miR-224 +miR-452 (High vs. Low ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1401 GABRE + miR-224 +miR-452 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1403 miR-224 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1404 miR-452 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1406 GABRE + miR-224 +miR-452+OAZ2 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1424 miR-7; miR-221; miR-222 miRNA Humans Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)] Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24760272
1425 miR-7; miR-221; miRNA Humans Upregulated in Early Castration Resistant Acquisition Prognostic Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months) miR-7: p=0.034; miR-221: p=0.036; Blood 24760272
1429 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1430 miR-19b miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1431 miR-345 miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1432 miR-519c-5p miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1433 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1434 miR-19b miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1435 miR-345 miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1436 miR-519c-5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1437 miR_19a+ miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1438 miR_19b+miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1439 miR_19a + miR_19b + miR_345 + miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1445 miR-1 miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.036 Tissue 24967583
1446 miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1447 miR-1 + miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1448 miR-361-3p miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.004 Prostate Secretion Samples 24976077
1449 mir-221 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.03 Prostate Secretion Samples 24976077
1450 mir-203 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p= 0.0002 Prostate Secretion Samples 24976077
1451 mir-133b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p < 0.01 Prostate Secretion Samples 24976077
1452 miR-361-3p + miR-361-3p+ mir-221+ mir-203 + mir-133b miRNA Humans Downregulated in PCa [miR-361-3p; miR-361-3p; mir-221; mir-133b]; Upregulated in PCa: [mir-203] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Prostate Secretion Samples 24976077
1469 miR-135a miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer And Adjacent Normal p<0.0001 Tissue 25065599
1470 miR-135a miRNA Humans Downregulated in GS ≥ 8 Prognostic Glesaon Score ≥ 8 and Gleason Score <8 p<0.01 Tissue 25065599
1471 miR-135a miRNA Humans Downregulated in Stage pT3a Prognostic Stage pT3a Vs Stage pT2c p<0.05 Tissue 25065599
1479 miR-30c miRNA Humans Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022) Diagnostic Benign Vs Malignant p=0.014 Tissue 25075250
1480 miR-219 miRNA Humans Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019) Diagnostic Benign Vs Malignant p=0.004 Tissue 25075250
1481 miR-21 miRNA Humans Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) Prognostic Gleason Score ≥ 8 Vs Gleason Score < 8 p=0.004 Tissue 25075250
1482 miR-21 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p<0.0001 Tissue 25075250
1483 miR-30c miRNA Humans Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.0003 Tissue 25075250
1484 miR-219 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.039 Tissue 25075250
1485 miR-21 miRNA Humans Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03) Prognostic Survival Vs No Survival p= 0.009 Tissue 25075250
1486 miR-30c miRNA Humans Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028) Prognostic Survival Vs No Survival p= 0.024 Tissue 25075250
1487 miR-30c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051) Prognostic PSA Recurrence Vs No Recurrence p= 0.003 Tissue 25075250
1488 let-7c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06) Prognostic PSA Recurrence Vs No Recurrence p=0.0266 Tissue 25075250
1492 mir-23b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1493 mir-27b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1494 mir-24-1 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1495 mir-27b miRNA Humans Decreased in patients with shorter progression free interval Prognostic Progression Vs No Progression p=0.0346 Tissue 25115396
1496 miR-1290 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1497 miR-1246 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1498 miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1499 miR-1290 + miR-375 + PSA + ADT miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p= 0.0016 Plasma 25129854
1500 miR-1290 + miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.05 Plasma 25129854
1534 miRNA-21 miRNA Humans Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.003 Serum 25190021
1535 miRNA-221 miRNA Humans Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.004 Serum 25190021
1553 miR-221 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46) Prognostic Recurrence Vs No Recurrence Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05 Tissue 25252191
1554 miR-21 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54) Prognostic Recurrence Vs No Recurrence p=0.0149 Tissue 25252191
1555 miR-141 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81) Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 25252191
1592 miRNA-483-5p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1593 miRNA-483-5p+ PSA miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1605 let‐7c miRNA Humans Downregulated in PCa (log 2 fold change: 0.7140) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1606 mir-145 miRNA Humans Downregulated in PCa (log 2 fold change: 0.4020) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1607 mir-221 miRNA Humans Downregulated in PCa (log 2 fold change: 0.5174) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1608 mir-21 miRNA Humans Upregulated in PCa (log 2 fold change: 0.6068) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1609 mir-182 miRNA Humans Upregulated in PCa (log 2 fold change: 0.8817) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1610 mir-145 miRNA Humans Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) Prognostic Gleason Score Upgradation Vs No Upgradation p=0.03 Tissue 31045265
1611 mir-221 miRNA Humans Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129) Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.04 Tissue 31045265
1639 miR-3162-5p miRNA Humans NA Prognostic Gleason grades 4+5 and 5 Vs Gleason grade 4 p=0.04 Tissue 31018918
1655 miR‐28; miR‐100; miR‐942; miR‐28‐3p miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐28: p=0.016; miR‐100: p=0.025; miR‐942: p=0.025; miR‐28‐3p: p=0.038 Plasma 30958910
1656 miR‐708; miR‐1298; miR‐886‐3p; miR‐374; miR‐376c; miR‐202; miR‐128a; miR‐185 miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐708: p<0.001; miR‐1298: p=0.001; miR‐886‐3p:p=0.01; miR‐374:p=0.017; miR‐376c: p=0.031; miR‐202: p=0.035; miR‐128a: p=0.039; miR‐185: p=0.041 Plasma 30958910
1697 hsa-miR-518a miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1698 hsa-miR-3605 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.033 Urine 26126436
1699 hsa-miR-16 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.04 Urine 26126436
1700 RUN6-2 miRNA Humans Downregulated in PCa (BPH: 4098.6; PCa: 2670.6) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1701 hsa-miR-615-3p miRNA Humans Downregulated in PCa (BPH: 8842.4; PCa: 2781.7) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1702 hsv1-miR-H18 miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1703 hsv2-miR-H9-5p miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1704 hsv1-miR-H18 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.004 Tissue+Urine+Serum 26126436
1705 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.002 Tissue+Urine+Serum 26126436
1706 hsa-miR-615-3p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1707 hsa-miR-BARTA-4 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1708 hsa-miR-4316 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Urine: p=0.022 Tissue+Urine+Serum 26126436
1709 hsv1-miR-H18 miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1710 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1725 miR-24+miR-30c+ Methylation Status of CRIP3 miRNA + DNA (Gene) Humans Increased in shorter BCR-free survival Prognostic Reclassification (Progression Vs No Progression) Univariate: p=0.008; Multivariate: p=0.017 Urine 30777394
1731 hsa‐mir‐891a; hsa‐mir‐892a; hsa‐mir‐1224; hsa‐mir‐93; hsa‐mir‐23c; hsa‐mir‐1251; hsa‐mir‐204; hsa‐mir‐323b; hsa‐mir‐200c; hsa‐mir‐96; miRNA Humans Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1747 miR-1260 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1748 miR-1274a miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1762 miR-1825 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1763 miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1764 miR-205 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1765 miR-141 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1766 let-7b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1767 miR-1825 miRNA Humans Downregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1768 let-7b miRNA Humans Upregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1769 miR-205 miRNA Humans Downregulated in PCa Prognostic Bone Metastasis Vs No Bone Metastasis p<0.05 Serum 30324582
1772 miR-141 miRNA Humans Upregulated in Bone Metastasis Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1773 tPSA+ hK2+ PCA3+ miR-141 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1849 miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1850 miR- 222-3p*+ miR-24-3p+ miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1851 miR- 222-3p*+ miR-24-3p+ miR-30c-5p+PSA miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1852 miR-425-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 30720162
1853 miR-425-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Cell Lines 30720162
1854 miR-424 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.043 Tissue 30345533
1855 miR-572 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1856 miR-572+ miR-424 miRNA Humans Upregulated in PC3 and DU145 Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1857 miR-572+ miR-424+ miR-1 + miR133b miRNA Humans Downregulated in Recurrent PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1919 miR-17* miRNA Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.040 Serum 25786615
1920 miR-200b* miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.045 Serum 25786615
1921 miR-210 miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.003 Serum 25786615
1922 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.27 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.031 Serum 25786615
1923 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.13 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.009 Serum 25786615
1924 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.02 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.015 Serum 25786615
1925 miR-551b miRNA Humans Upregulated in PCa [mean PC/mean]: (2.30 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.017 Serum 25786615
1926 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (14.66 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.01 Serum 25786615
1927 miR-562+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.12 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1928 miR-562+ miR-210+ miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (17.39 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1929 miR-562+ miR-210+ miR-501-3p+ miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.72 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1930 miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1931 let-7a* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.012 Serum 25786615
1932 miR-200b* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1933 miR-210 miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.01 Serum 25786615
1934 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.038 Serum 25786615
1935 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.014 Serum 25786615
1936 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1937 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.03 Serum 25786615
1938 miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.05 Serum 25786615
1939 let-7a*+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1940 let-7a*+ miR-210+ miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1941 let-7a*+ miR-210+ miR-562+ miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1942 let-7a*+ miR-210+ miR-562+ miR-616+ miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615